
Chinese woman with undersized chest muscles wears ‘jewellery breast' to boost self-esteem
Advertisement
The woman, surnamed Xuan, was born with Poland Syndrome, a condition characterised by underdeveloped chest muscles and limbs on one side of the body.
The syndrome occurs in about one in every 30,000 births, and affects males twice as often as females.
It does not affect life expectancy, but patients are often advised to receive reconstruction or implant surgery to help with breathing problems and appearance based on the severity of their condition.
Xuan said she suffered from low self-esteem when she was a child, knowing that she looked different from her classmates.
Xuan, right, was born with Poland Syndrome, a condition characterised by underdeveloped chest muscles and limbs on one side of the body. Photo: handout
She said she tried to stuff her bra to make her breasts look symmetrical, and habitually slouched to hide her abnormality.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Hims & Hers Q2 2025: What You Need to Know Ahead of Earnings
Hims & Hers Health (NYSE:HIMS) reports Q2 2025 earnings after U.S. markets close on Monday, August 4. Analysts expect revenue of around $552 million, up 75% YoY, and adjusted EPS near $0.15, roughly up 15% YoY. Despite the volatility, shares are up 154% YTD, pushing the forward P/E to roughly 57. Subscriber growth remains the core engine investors care about. Subscribers increased 38% in Q1, reaching 2.4 million. Weight-loss GLP-1 offerings are a swing factor, but Novo Nordisk (NYSE:NVO) ended its partnership on 23 Jun 2025, citing illegal mass compounding and deceptive marketing, which sent Hims down 30%. Analysts estimate that up to half of Hims' projected weight-loss revenue could be at risk. Investors need clarity on FDA scrutiny, formulary access, and whether compounded semaglutide margins can hold. Marketing spend, revenue per average user, and progress on the ZAVA integration will also be closely watched. Management guides FY25 revenue of $2.32.4 billion and low-teens EBITDA margins. Any uplift to those guides or clean regulatory commentary could keep momentum intact. But with valuation stretched, even a top-line beat may disappoint if churn ticks up or compliance costs bite. Q2 will test whether the telehealth disrupter can scale responsibly before regulators step in. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
NYSE names Bryan Daniel as president of NYSE Texas
(Reuters) -The New York Stock Exchange said on Monday it has named Bryan Daniel, a former staffer of Texas Governor Greg Abbott, as the president of NYSE Texas. The move comes months after Intercontinental Exchange-owned NYSE said it would launch in Texas, as the state emerges as a financial hub and a challenger to New York. Daniel will report to Lynn Martin, president of the NYSE Group. Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
AI Glasses Could Replace Smartphones, Zuckerberg Says
Meta Platforms (NASDAQ:META) is pushing a post-iPhone era with AI-powered glasses, recasting the smartphone as yesterday's interface. Investors are weighing in whether Zuckerberg's personal superintelligence vision can move from manifesto to mainstream. Warning! GuruFocus has detected 5 Warning Sign with META. He says the glasses will know users deeply, understand goals and help achieve them, and the company is piling on AI talent to build standalone versions that no longer need a phone. Right now the Ray-Ban smartglasses still lean on smartphones, but the roadmap is toward independent multimodal displays. Apple is defending the iPhone's role, while rivals are racing too: Amazon bought wearable startup Bee and Sam Altman is teaming with Jony Ive on a secret AI device. The shift in tone at Meta, from past hardware misses to a more urgent, existential pitch, is meant to turn skepticism into a narrative of necessity. This article first appeared on GuruFocus. Sign in to access your portfolio